ReviewPolymers2018
Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery Systems.
Review in Polymers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed.
- Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study.The British journal of ophthalmology · 2026Trial
- Liposomal Drug Delivery in Ocular Therapy: Strategies for Enhancing Corneal Penetration and Bioavailability.Cells · 2026Review
- Advancing Treatment of Degenerative Eye Diseases at the Nanoscale.Smart medicine · 2026Review
- Article
- Transcriptome Analysis of TGFBI Knockdown vs Normal Corneal Epithelial Cells: Implications for TGFBI Corneal Dystrophy Treatment.Biochemical genetics · 2026Article
- Dual-Responsive Chitosan-Grafted PNIPAAm Hydrogel Eye Drop Incorporating Insulin-Imprinted Microgels for Dry Eye Syndrome Treatment.Macromolecular bioscience · 2026Article
- Recent Advances in Extended Ocular Drug Delivery for the Ocular Surface.Molecules (Basel, Switzerland) · 2026Review
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- Anatomically Guided Non-Viral CRISPR/Cas9 Delivery in the Eye: Overcoming Barriers for Precision Gene Therapy.Pharmaceutics · 2026Review
- Exploring the Potential of Transdermal Nanobilosomal Gel for Magnified Anti-Inflammatory Efficacy of Thymol for Managing Rheumatoid Arthritis.Gels (Basel, Switzerland) · 2026Article
- Advances in the management of ocular anterior segment diseases using biomaterials-based drug delivery systems.Journal of biomaterials applications · 2026Review
- Innovations in mRNA-Based Nanoparticle for the Treatment of Ocular Disorders: A Comprehensive Review.Current pharmaceutical design · 2026Review
- Targeting Ocular Tissue through Surface-Modified and Multifunctional Biomaterials and mRNA-Based Therapeutics.Current pharmaceutical design · 2026Review
- Preservative-Free Gel-Formulated Glaucoma Therapies: Learning from the Past, Looking to the Future.Advances in therapy · 2025Review
- Enhanced Ocular Delivery of Epalrestat Using Nanostructured Lipid Carrier Laden Soft Contact Lens.Pharmaceutics · 2025Article
- Efficacy, bioavailability, and intracellular delivery of nanoparticle based drug encapsulated carbon for antiviral therapy.Scientific reports · 2025Article
- Nanovesicular Drug Delivery Systems for Rare Ocular Diseases: Advances, Challenges, and Future Directions.AAPS PharmSciTech · 2025Review
- Therapeutic targeting of ocular diseases with emphasis on PI3K/Akt, and OPRL pathways by Hedera helix L. saponins: a new approach for the treatment of Pseudomonas aeruginosa-induced bacterial keratitis.Natural products and bioprospecting · 2025Article
- Topical Ocular Drug Delivery: The Impact of Permeation Enhancers.Pharmaceutics · 2025Review
- ZnFe Layered Double Hydroxide Nanosheets Loaded with Cu Single-Atom Nanozymes with Multi-Enzyme-Like Catalytic Activities as an Effective Treatment for Bacterial Keratitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The main inconvenience of conventional eye drops is the rapid washout of the drugs due to nasolacrimal drainage or ophthalmic barriers. The ocular drug bioavailability can be improved by either prolonging retention time in the cul-de-sac or by increasing the ocular permeability. The focus of this review is to highlight some chitosan-based drug delivery approaches that proved to have good clinical efficacy and high potential for use in ophthalmology. They are exemplified by recent studies exploring in-depth the techniques and mechanisms in order to improve ocular bioavailability of the active substances. Used alone or in combination with other compounds with synergistic action, chitosan enables ocular retention time and corneal permeability. Associated with other stimuli-responsive polymers, it enhances the mechanical strength of the gels. Chitosan and its derivatives increase drug permeability through the cornea by temporarily opening tight junctions between epithelial cells. Different types of chitosan-based colloidal systems have the potential to overcome the ocular barriers without disturbing the vision process. Chitosan also plays a key role in improving corneal wound healing by stimulating the migration of keratinocytes when it is used alone or in combination with other compounds with synergistic action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.